What Actoveerco Pharmaceutical Company does

Actoverco Pharmaceutical Company is Iran's largest private pharmaceutical group, operating five dedicated manufacturing facilities and employing more than 2,000 people, including 1,000+ at production and research sites. The company produces a portfolio of more than 320 pharmaceutical products across 15 therapeutic areas, including infectious diseases, respiratory, gastrointestinal, neurological, psychiatric, cardiovascular, diabetes, transplant/oncology, dermatology, gynecology, nephrology, and pain management. Notable recent launches include Tirzacto (tirzepatide) and Semacto (semaglutide) for diabetes and weight management, Kinerin (finerenone) for kidney protection, and combinations such as Naperco (esomeprazole/naproxen) and Manazil (donepezil/memantine). The company also produced the Sputnik V COVID-19 vaccine through a technology transfer partnership with RDIF and the Gamaleya Institute.

The company's business model is based on direct sales of generic and branded generic pharmaceuticals across Iran through hospital procurement tenders, retail pharmacy distribution, and direct relationships with healthcare providers. It generates revenue through product sales rather than licensing or recurring fees, with pricing not publicly disclosed and subject to Iran's domestic pharmaceutical price controls. The company also operates an export channel, distributing products to regional and international markets through co-marketing partnerships with Merck, KRKA, Ferrer, Hetero, Amega Biotech, and Laboratorios Rubio. The company is privately held with no public listing, ticker, or disclosed institutional ownership.

Actoverco's go-to-market combines a sales-led domestic model (Iranian public/private hospital procurement, retail pharmacies, healthcare provider engagement) with channel-partner-driven international distribution. Customer engagement is supported by a health-education blog (Salam Salamat), active social media presence, trade show participation, and direct outreach including manufacturing facility visits for healthcare professionals. The company holds GMP-certified facilities compliant with both Iranian and international regulatory standards, and its biotech production lines have been validated by Russian authorities for Sputnik V vaccine authenticity and efficacy.

Name

Actoveerco Pharmaceutical Company

Legal name

Actoverco Pharmaceutical Company

Website

https://actoverco.com

Company type

Private

Founded year

1972

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Actoverco Pharmaceutical Company is Iran's largest private pharmaceutical group, operating 5 factories and 320+ products across 15 therapeutic areas. It serves Iranian patients and the healthcare system through hospital procurement, retail pharmacies, and export distribution via international partners.

Ownership category

akta.pro rank

Product category

Generic Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

akta.pro secondary industries

Vaccine Manufacturing & Fill-Finish (HLAIAEAJ), Vaccine Fill-Finish, Packaging & Cold-Chain Formulation (vial/syringe, lyophilization, thermostable) (HLAAAEAJ)

Keywords

• Generic pharmaceuticals
• Pharmaceutical manufacturing
• Biopharmaceutical production
• Vaccine manufacturing
• Therapeutic medications

Headquarters

HQ city

Tehran

HQ country

Iran

HQ region

Middle East

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Product Sales: Sale of generic and branded generic pharmaceutical products across 15 therapeutic areas through domestic hospital procurement, retail pharmacy distribution, and direct sales to healthcare providers in Iran and export markets.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

Actoverco manufactures and distributes generic and branded generic pharmaceutical products across 15 therapeutic areas through 5 GMP-certified production facilities, producing more than 320 products. The company also operates biotechnology/vaccine production lines, including the domestically produced Sputnik V COVID-19 vaccine developed through technology transfer from the Gamaleya Institute. Products are sold through Iranian hospital procurement, retail pharmacy networks, and international export partnerships.

Product overview

Actoverco Pharmaceutical Company is Iran's largest private pharmaceutical group, operating across 15 therapeutic areas with over 320 pharmaceutical products. The portfolio includes treatments for infectious diseases, respiratory conditions, gastrointestinal disorders, multiple sclerosis, kidney/urinary diseases, neurological disorders, psychiatric conditions, dermatology, gynecology, cardiovascular diseases, transplant/cancer support, diabetes, and pain management. Key products include tirzepatide (تیرزکتو) and semaglutide (سماکتو) for diabetes and weight management, finerenone (کینرین) for kidney protection, esomeprazole/naproxen combination (ناپرکو), donepezil/memantine (مانازیل) for Alzheimer's, nicorandil (آدینکو) for angina, ramelteon (راملی) for insomnia, and trikolofid (تریکوفید) for hair loss. The company also produced the Sputnik V COVID-19 vaccine. Actoverco maintains 5 production facilities with approximately 1,000-2,000 employees and holds international certifications for quality standards.

Differentiator

Problem solved

Functional benefit

Brands

• Tirzacto (تیرزکتو): Tirzepatide injection for diabetes and weight management
• Semacto (سماکتو)
• Adinco (آدینکو)
• Kinerin (کینرین)
• Naperco (ناپرکو)
• Manazil (مانازیل)
• Nexus (نکسوس)
• Trikofid (تریکوفید)
• Ramily (راملی)

Products and services

• Tirzacto (Tirzepatide) A tirzepatide injectable medication for the treatment of type 2 diabetes and weight management, marketed by Actoverco as a new generation therapy in Iran.
• Semacto (Semaglutide) A semaglutide injectable medication for diabetes treatment and weight management, marketed by Actoverco under the brand Semacto.
• Kinerin (Finerenone) A finerenone medication for kidney protection in patients with chronic kidney disease associated with type 2 diabetes.
• Naperco (Esomeprazole/Naproxen) A combination product containing esomeprazole and naproxen for pain relief with gastric protection.
• Manazil (Donepezil/Memantine) A combination medication containing donepezil hydrochloride and memantine hydrochloride for the treatment of Alzheimer's disease.
• Adinco (Nicorandil) A potassium channel activator medication for the treatment of chronic and stable chest pain (angina pectoris), available in 10mg and 20mg scored tablets.
• Ramily (Ramelteon) An FDA-approved prescription sleep medication for individuals with difficulty initiating sleep, produced by Actoverco without the side effects of typical sleep aids.
• Sputnik V COVID-19 Vaccine Sputnik V COVID-19 vaccine produced by Actoverco at its biotech production facilities, with planned monthly capacity of 900,000 doses of Sputnik V or 3.5 million doses of Sputnik Light supplied to the Iranian Ministry of Health.

Named customers3 records

Segments1 record

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Six partnerships are on record, tiered flagship, major and notable.

• RDIF (Russian Direct Investment Fund) / Gamaleya InstituteflagshipTechnology or Integration · 1 January 2021Strategic technology transfer and production partnership for Sputnik V COVID-19 vaccine. Actoverco completed full technology transfer from the Gamaleya Institute in Russia, with production batches verified by Russian authorities. RDIF coordinated the international production network. Planned monthly supply of 900,000 doses of Sputnik V or 3.5 million doses of Sputnik Light to the Iranian Ministry of Health.
• MerckmajorTechnology or IntegrationMerck (global pharmaceutical company) is listed as a key commercial partner of Actoverco, with Merck-branded products distributed through Actoverco's Iranian market presence. Actoverco distributes Merck products in Iran under product category listings.
• FerrermajorTechnology or IntegrationSpanish pharmaceutical company Ferrer is identified as a commercial partner of Actoverco, collaborating on product distribution and market presence in Iran.
• Amega BiotechnotableTechnology or IntegrationAmega Biotech is listed as a commercial partner collaborating with Actoverco in the pharmaceutical sector.
• KRKAmajorTechnology or IntegrationSlovenian pharmaceutical company KRKA is identified as a key commercial partner, with established product and market collaboration with Actoverco.
• HeteronotableTechnology or IntegrationIndian pharmaceutical company Hetero (Hetero World) is listed as a commercial partner of Actoverco, collaborating on pharmaceutical product supply and distribution.

Scale indicators5 records

Recent moves5 records

Expansion highlights10 records

Regional players

• Laboratorios Rubio: Spanish specialty/generic pharmaceutical company listed as an Actoverco commercial partner. Comparable as a mid-sized European generics manufacturer using co-marketing partnerships to access new geographies.
• Ferrer: Spanish private pharmaceutical group with branded generics across multiple therapeutic areas. Already an Actoverco partner, Ferrer is comparable in therapeutic breadth and partnership-driven emerging-markets expansion.

Direct peers

• Darou Pakhsh Pharma Manufacturing: One of Iran's largest pharmaceutical manufacturers, producing a broad range of finished dosage form generics across multiple therapeutic areas. Directly comparable as a domestic Iranian pharma manufacturer competing for institutional tenders and retail pharmacy distribution.
• KRKA: Slovenia-headquartered leading European generic pharmaceutical manufacturer with a broad finished dosage portfolio across multiple therapeutic areas. Already an Actoverco commercial partner, KRKA is directly comparable in generic FDF scope and export-driven emerging-markets strategy.
• Hetero (Hetero Labs / Hetero Biopharma): India-based global generic manufacturer with strong biosimilars and vaccine manufacturing footprint. Already partnered with Actoverco, Hetero is a comparable emerging-markets generics competitor with vertically integrated API and FDF capabilities.
• TPICO (Tamin Pharmaceutical Investment Company): Major state-affiliated pharmaceutical holding in Iran with a portfolio spanning manufacturing, distribution, and retail pharmacy across many therapeutic areas. Closest scaled Iranian pharma peer with which Actoverco competes for public-sector procurement volumes.

Broad incumbents

• Cipla: Indian multinational with a broad generics portfolio and historically strong presence in emerging markets including Africa, the Middle East, and Iran-aligned regions. Comparable in finished dosage generics at scale and government tender experience.
• Torrent Pharmaceuticals: India-based generic and branded-generic pharmaceutical company with strong chronic-disease portfolio (cardiovascular, diabetes, neurological). Comparable therapeutic mix and emerging-markets export orientation make it a relevant regional-scale benchmark.
• Aurobindo Pharma: Large Indian generic pharmaceutical company with extensive finished dosage portfolio and growing biosimilars/biologics exposure. Comparable to Actoverco in scaling generic FDF across therapeutic areas and pursuing emerging-markets expansion.

Emerging players

• Strides Pharma Science: India-headquartered generics manufacturer focused on regulated and emerging markets. Comparable as a smaller-scale but internationally-oriented generic platform competing across multiple therapeutic categories.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/Actoverco1
• LinkedInlinkedin.com/company/actover
• Instagraminstagram.com/actoverco.official

Revenue estimate

Valuation estimate

Number of profiles

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Actoveerco Pharmaceutical Company